What is William Blair's Forecast for VERV FY2024 Earnings?

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Analysts at William Blair raised their FY2024 earnings per share estimates for shares of Verve Therapeutics in a research note issued to investors on Tuesday, November 5th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($2.32) for the year, up from their prior forecast of ($2.41). The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.65) per share. William Blair also issued estimates for Verve Therapeutics' Q4 2024 earnings at ($0.55) EPS, Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.63) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.67) EPS and FY2025 earnings at ($2.63) EPS.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.11. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The firm had revenue of $6.87 million for the quarter, compared to analyst estimates of $2.75 million. During the same quarter last year, the firm earned ($0.72) earnings per share. The company's revenue for the quarter was up 120.2% on a year-over-year basis.

Several other research firms have also recently weighed in on VERV. HC Wainwright lowered their price objective on shares of Verve Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday. Royal Bank of Canada decreased their price objective on Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating for the company in a research report on Wednesday. Finally, Canaccord Genuity Group increased their price objective on Verve Therapeutics from $29.00 to $32.00 and gave the stock a "buy" rating in a report on Wednesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $25.75.

Verve Therapeutics Trading Down 1.1 %

VERV traded down $0.07 on Friday, hitting $6.29. 493,500 shares of the stock traded hands, compared to its average volume of 1,302,925. Verve Therapeutics has a 52 week low of $4.30 and a 52 week high of $19.34. The firm has a market capitalization of $532.51 million, a PE ratio of -2.59 and a beta of 1.75. The business has a fifty day moving average price of $5.48 and a two-hundred day moving average price of $5.70.

Institutional Investors Weigh In On Verve Therapeutics

A number of hedge funds have recently added to or reduced their stakes in VERV. Accredited Investors Inc. raised its stake in shares of Verve Therapeutics by 14.3% during the 3rd quarter. Accredited Investors Inc. now owns 20,000 shares of the company's stock worth $97,000 after purchasing an additional 2,500 shares during the period. Aigen Investment Management LP purchased a new stake in Verve Therapeutics during the 3rd quarter worth about $74,000. Los Angeles Capital Management LLC lifted its holdings in shares of Verve Therapeutics by 8.2% in the third quarter. Los Angeles Capital Management LLC now owns 262,393 shares of the company's stock worth $1,270,000 after buying an additional 19,925 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in Verve Therapeutics by 78.7% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 53,524 shares of the company's stock valued at $259,000 after purchasing an additional 23,565 shares during the period. Finally, US Bancorp DE grew its position in Verve Therapeutics by 1,631.7% during the third quarter. US Bancorp DE now owns 18,806 shares of the company's stock worth $91,000 after buying an additional 17,720 shares in the last quarter. Institutional investors and hedge funds own 97.11% of the company's stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.